rhinosinusitis%20-%20acute,%20bacterial
RHINOSINUSITIS - ACUTE, BACTERIAL
Acute bacterial rhinosinusitis is the mucosal inflammation of the nose and paranasal sinuses caused by bacteria lasting ≥10 days for up to 4 weeks with no clinical improvement, severe signs or symptoms [eg high fever (39°C), purulent nasal discharge, facial pain] of ≥3-4 consecutive days, and worsening of symptoms within 10 days after initial improvement.
It is often preceded by a viral upper respiratory tract infection, rhinitis or other conditions that impair local or systemic immune function (eg nonallergic rhinitis, dental infection, mechanical obstruction of the nose, cystic fibrosis, ciliary dysfunction, immunodeficiency that impair the sinus drainage).
Signs and symptoms are nonspecific and typically difficult to differentiate from viral upper respiratory tract infection.
There is fever with nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without facial pressure/pain/fullness and reduction/loss of smell.
Streptococcus pneumoniae and unencapsulated strains of Haemophilus influenzae cause half of acute rhinosinusitis cases.

Rhinosinusitis%20-%20acute,%20bacterial Signs and Symptoms

Definition

  •  Acute rhinosinusitis is defined as sudden onset of ≥2 of the following symptoms for <12 weeks:
    • Nasal blockage/obstruction/congestion
    • Facial pain/pressure
    • Reduced or loss of smell
  • Acute bacterial rhinosinusitis is defined as mucosal inflammation of the nose and paranasal sinuses caused by bacteria lasting ≥10 days for up to 4 weeks with no clinical improvement, severe signs or symptoms [eg high fever (39°C), purulent nasal discharge, facial pain] of ≥3-4 consecutive days, and worsening of symptoms within 10 days after initial improvement
  • Often preceded by a viral upper respiratory tract infection (URTI), rhinitis or other conditions that impair local or systemic immune function (eg nonallergic rhinitis, dental infection, mechanical obstruction of the nose, cystic fibrosis, ciliary dysfunction, immunodeficiency that impair the sinus drainage)
  • Incidence in women is higher than men

Etiology

  • S pneumoniae and unencapsulated strains of H influenzae cause approximately 75% of acute rhinosinusitis cases
  • M catarrhalis account for 2-10% of the cases and is more common among children
  • 3-7% of the cases may be due to S pyogenes and anaerobic bacteria
  • S aureus and other Streptococcal sp may occasionally cause rhinosinusitis
  • Rarely Gram-negative bacilli are recovered in cases of acute rhinosinusitis
  • Microaerophilic and anaerobic bacteria may be identified and isolated if the acute bacterial rhinosinusitis (ARBS) is due to the extension of dental root infection to the sinus cavity

Pathophysiology

  • Occurs as a complication of a viral infection
    • Can be associated with rhinitis or other conditions that obstruct the nose or impair immune function (local or systemic)

Signs and Symptoms

  • Signs and symptoms are nonspecific and it is typically difficult to differentiate from viral upper respiratory tract infection (URTI)
  • There is nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without
    • Facial pressure/pain/fullness
    • Reduction/loss of smell
  • Other signs and symptoms include fever, fatigue, headache, ear pressure/discomfort, throat pain, halitosis, maxillary dental pain, facial swelling or periorbital edema, cough

Risk Factors

  • Most common predisposing factor to acute bacterial rhinosinusitis (ABRS) is viral upper respiratory tract infection (URTI)
  • Other factors:
    • Presence of medical conditions (eg allergic rhinitis, vasomotor rhinitis, cystic fibrosis, immunodeficiency, Kartagener syndrome)
    • Irritants (eg environmental tobacco smoke, air pollution, chlorine)
    • Anatomic (eg deviated nasal septum, adenoidal hypertrophy, immotile cilia, polyps, tumors and foreign bodies, granulomatosis with polyangitis)
    • Odontogenic sources
    • Medications (eg overuse of topical decongestants, cocaine abuse)
    • Trauma (eg dental procedure, diving)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 6 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 06 Aug 2020
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.